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Abstract
Background: Several randomized trials have indicated that combination chemotherapy applied in metastatic
colorectal cancer (mCRC) does not significantly improve overall survival when compared to the sequential use of
cytotoxic agents (CAIRO, MRC Focus, FFCD 2000-05). The present study investigates the question whether this
statement holds true also for bevacizumab-based first-line treatment including escalation- and de-escalation strategies.
Methods/Design: The AIO KRK 0110/ML22011 trial is a two-arm, multicenter, open-label randomized phase III trial
comparing the efficacy and safety of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan
plus bevacizumab (CAPIRI-Bev) in the first-line treatment of metastatic colorectal cancer. Patients with unresectable
metastatic colorectal cancer, Eastern Cooperative Oncology Group (ECOG) performance status 0-1, will be assigned
in a 1:1 ratio to receive either capecitabine 1250 mg/m
2 bid for 14d (d1-14) plus bevacizumab 7.5 mg/kg (d1) q3w
(Arm A) or capecitabine 800 mg/m
2 BID for 14d (d1-14), irinotecan 200 mg/m
2 (d1) and bevacizumab 7.5 mg/kg
(d1) q3w (Arm B). Patients included into this trial are required to consent to the analysis of tumour tissue and
blood for translational investigations. In Arm A, treatment escalation from Cape-Bev to CAPIRI-Bev is recommended
in case of progressive disease (PD). In Arm B, de-escalation from CAPIRI-Bev to Cape-Bev is possible after 6 months
of treatment or in case of irinotecan-associated toxicity. Re-escalation to CAPIRI-Bev after PD is possible. The
primary endpoint is time to failure of strategy (TFS). Secondary endpoints are overall response rate (ORR), overall
survival, progression-free survival, safety and quality of life.
Conclusion: The AIO KRK 0110 trial is designed for patients with disseminated, but asymptomatic mCRC who are not
potential candidates for surgical resection of metastasis. Two bevacizumab-based strategies are compared: one starting
as single-agent chemotherapy (Cape-Bev) allowing escalation to CAPIRI-Bev and another starting with combination
chemotherapy (CAPIRI-Bev) and allowing de-escalation to Cape-Bev and subsequent re-escalation if necessary.
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EudraCT-No.: 2009-013099-38
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Colorectal cancer (CRC) is the second leading cancer
entity in Germany with an incidence of approximately
71.000 and about 30.000 deaths every year. With a median
age of about 70 years, many elderly patients are affected
by this disease. In about 20% of patients synchronous
metastasis is apparent at first diagnosis, while 20% to 25%
of patients develop metachronous metastasis. Unfortu-
nately, only 10% to 20% of mCRC patients are resectable
at the time of presentation [1,2].
Three major groups of mCRC patients can be differen-
tiated: 1. Patients with resectable colorectal cancer. 2.
Patients with potentially resectable metastasis that
require intensive combination therapy to convert the dis-
ease to a resectable state. Combination chemotherapy is
also necessary in patients with symptomatic or rapidly
progressive disease. 3. Patients with disseminated multi-
ple metastases, who are not potential candidates for
resection and who present with mostly asymptomatic,
not rapidly progressing disease. These patients do not
necessarily benefit from rapid remission induction or
high overall response rates. So far, most randomised
trials have not aimed to clearly separate these groups in
order to apply distinctly different therapies.
Therefore, less intensive regimens focusing on survival
and disease control may be a better choice for first-line
treatment in these patients. Grothey et al. analyzed the
AVF2107g and N9741 trial and identified tumour response
not as a necessary factor to provide benefit to an individual
patient in first-line therapy for metastatic colorectal cancer
(mCRC). Although patients achieving response had a better
prognosis, response was not predictive of the benefit
derived from the superior treatment in either trial [3].
The combination of a fluoropyrimidine plus bevacizu-
mab was previously shown to be effective in the first-line
treatment for mCRC and demonstrated progression-free
survival times of 8 to 9 months and disease control rates
(DCR) of 69%-92.5% [4,5]. Also low rates of progressive
disease (<10%) have been reported in this treatment
regimen.
The use of the oral fluoropyrimidine capecitabine in
combination with bevacizumab was previously shown to
be safe and effective in the first-line treatment of mCRC.
In a recent report, this combination allowed a DCR of
92% and a PFS of 8.5 months [5]. By comparison, the
combination of capecitabine with irinotecan (CAPIRI)
plus bevacizumab induced a disease control rate of 72%-
82% and a PFS of 9-12 months [6,7]. Earlier trials evalu-
ating chemotherapy regimen with capecitabine and irino-
tecan had reported unacceptable incidences of severe
gastrointestinal adverse effects with grade 3/4 diarrhea
up to 36% of patients [8-10]. We therefore decided for a
20% dose reduction (i.e., capecitabine 800 mg/m2,
irinotecan 200 mg/m2) previously investigated in two
AIO randomized phase II trials [7,11]. Acceptable gastro-
intestinal toxicity with grade3 - 4d i a r r h o e ao c c u r r i n gi n
15.7%-21.0% of patients has been reported for the combi-
nation of capecitabine and irinotecan [7,9,11]. The data
from the two AIO trials also demonstrated that while
both, CAPOX and CAPIRI, regimens are highly active
and safe, the absence of sensory neuropathy favours
CAPIRI as the chemotherapy backbone for bevacizumab
in this first-line mCRC trial.
The AIO KRK 0110 trial investigates the combination
of capecitabine and bevacizumab (Cape-Bev) versus the
combination of capecitabine, irinotecan bevacizumab
(CAPIRI-Bev). This trial is designed to investigate two
different treatment strategies for unresectable, dissemi-
nated, but asymptomatic metastatic colorectal cancer
patients with the goal of long-term disease stabilization
and moderate toxicity.
In case of first occurrence of progressive disease
(PFS-1) in the Cape-Bev-arm, treatment is escalated by
adding irinotecan (CAPIRI-Bev). PFS-2 can be investi-
gated in patients developing SD or PR/CR after treat-
ment intensification.
In the comparator arm, patients receive CAPIRI + bev-
acizumab (CAPIRI-Bev) as first-line therapy. De-escala-
tion to Cape-Bev is allowed after 6 months of treatment
or in case of irinotecan-induced toxicity. The primary
endpoint is the time to failure of strategy (TFS). Toxicity
will be evaluated according to NCI CTC using a prede-
fined score system accounting for symptomatic grade 2-4
toxicities per cycle in case of comparable TFS times.
Quality of life assessment is performed in both treat-
ment arms to investigate the impact of monochemother-
apy and combination chemotherapy during first-line
therapy. Vice versa, differences in treatment efficacy and
reduction of cancer-related symptoms will be correlated
b yq u a l i t yo fl i f ea n a l y s e su s i n gt h eE O R T C - Q L Q - C 3 0
questionnaire.
Methods/Design
Primary objective
The primary objective is to investigate the efficacy of both
treatment strategies in the first-line treatment of patients
with unresectable mCRC. Since the sequential application
of treatment regimens is evaluated, time to failure of strat-
egy (TFS) was chosen as the primary endpoint (Figure 1).
In the Cape-Bev arm, treatment may be escalated after
disease progression (PFS-1) by addition of irinotecan
(CAPIRI-Bev); PFS-2 can then be investigated in
patients after treatment intensification. In the experi-
mental Cape-Bev arm, time to failure of strategy (TFS)
is defined as PFS-1 + PFS-2, where PFS-1 is the time
between randomization and first failure of Cape-Bev,
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Page 2 of 11and PFS-2 is the time between PFS-1 and PD after treat-
ment intensification to CAPIRI-Bev.
In the CAPIRI-Bev comparator arm, treatment may be
de-escalated to Cape-Bev and re-escalated to CAPIRI-
Bev according to a predefined algorithm. TFS is defined
a st h et i m eb e t w e e nr a n d o m ization and progression on
the CAPIRI-Bev treatment strategy.
In case of comparable TFS times in both study arms,
toxicity will be evaluated according to NCI CTC in a pre-
defined score system using symptomatic grade 2-4 toxici-
ties per cycle.
Secondary objective
Secondary objectives are to compare overall response rate
(ORR), PFS-1, PFS-2 (experimental arm only), overall sur-
vival (OS), safety, toxicity and quality of life. Survival is
defined as the interval between randomization and death
of any cause. The grade of toxicity will be assessed using
the NCI-CTC criteria version 4.0. Quality of life will be
studied by means of the EORTC QLC C30 questionnaire.
Design
The AIO KRK 0110 ML22011 trial is a two-arm, multi-
center, open-label randomized phase III trial comparing
the efficacy and safety of capecitabine plus bevacizumab
versus capecitabine plus irinotecan plus bevacizumab in
the first-line treatment of metastatic colorectal cancer.
This trial is designed for patients with disseminated, but
asymptomatic metastatic disease in good general condition
(ECOG 0-1) who may not benefit from aggressive first-line
treatment according to the definition of group-3 defined in
the German S3-guidelines for colorectal cancer [12,13].
Enrolment
A total of 516 patients will be enrolled in a 1:1 randomi-
zation into the two treatment arms. Patients will be
enrolled in 80 to 100 study centres. The study started
on December, 21
st 2010. The estimated primary comple-
tion date is December 2013 (Final data collection date
for primary outcome measure) and the estimated study
completion date is December 2016.
Stratification
Treatment assignment will be stratified, based on:
1. Prior adjuvant chemotherapy or no prior adjuvant
chemotherapy
2. White-blood-cell count <8.000/μl vs. > 8.000/μl
CAPIRI
CAPIRI
Cape-Bev vs CAPIRI-Bev
de-escalation in case of toxicity
to Cape-Bev and subsequent
re-escalation to CAPIRI-Bev
possible within the trial design.
continuation until PD
continuation until PD
escalation
at PD
CAPIRI 
+ 
Bev
CAPIRI 
+ 
Bev
Cape
+ 
Bev
Figure 1 Flow chart of the AIO KRK 0110 Trial/ML22011 Trial. Patients are randomized to either receive single-agent chemotherapy (Cape-
Bev) and escalation to CAPIRI-Bev at progressive disease or combination chemotherapy (CAPIRI-Bev) with an de-escalation option to Cape-Bev
and subsequent re-escalation if necessary.
Giessen et al. BMC Cancer 2011, 11:367
http://www.biomedcentral.com/1471-2407/11/367
Page 3 of 113. Alkaline phosphatase <300 U/l vs. > 300 U/l
Eligibility criteria
Inclusion criteria
￿ Written informed consent
￿ Histologically confirmed adenocarcinoma of the
colon or rectum
￿ Stage IV disease considered irresectable or patient
declining surgery
￿ No prior chemotherapy for metastatic disease
￿ Metastatic disease evaluable according to RECIST
version 1.1 (CT scan of thorax and abdomen within
4 weeks before randomization)
￿ Age 18 years and older
￿ ECOG 0-1
￿ Life expectancy > 3 months
￿ Assessment of KRAS status (local assessment,
result not requested at time of randomization)
￿ Patient agreed storage of tumour tissue for mole-
cular analyses and genetic profiling
￿ Time to previous adjuvant chemotherapy > 6
months
￿ No surgery within 28 days prior to treatment start.
No cytological biopsies, implantation of venous port
system within 7 days prior to treatment start. Opera-
tion sequels need to be completely healed. Major
operations must not be expected at time of study
begin, except for potential secondary resection of liver
metastases. In case of secondary resection of liver
metastases, bevacizumab must be discontinued 6-8
weeks prior to surgery.
￿ Effective contraception in childbearing potential
women
￿ Precluded pregnancy
￿ Normal cardiac function (ECG and cardiac ultra-
sound) with LVEF >= 55%
￿ INR <1.5 and APTT <1.5 ULN in patients without
anticoagulant medication. Therapeutic anticoagulation
is allowed if INR and APTT are in the therapeutic
range and stable for at least 2 weeks
￿ Continuous medication with acetylsalicylic acid is
allowed up to a daily dose of 325 mg. Clopidogrel is
allowed up to a recommended daily dose of 75 mg.
Ticlodipine is allowed up to a recommended daily
dose of 500 mg. Combination of acetylsalicylic acid
and clopidogrel or ticlodipine is not allowed.
￿ Urine dipstick < 2+ for protein. In patients with >=
2 + protein a 24-hour-urine collection should be
performed and proteinuria should be <= 1 g/24 h
￿ Adequate hematologic function: leukocytes >=
3000/μl, neutrophils >= 1500/μl, platelets >=
100.000/μ, and haemoglobin >= 9 g/dl.
￿ Adequate hepatic function: Bilirubin <= 1,5× upper
limit of normal (ULN). ALAT and ASAT <= 2,5×
ULN, in case of liver metastases <= 5× ULN
￿ Adequate renal function: Serum creatinine <= 1,5×
ULN or creatinine clearance (GFR Cockroft and
Gault >= 50 ml/min)
Exclusion Criteria
￿ Primary resectable metastases or patients request-
ing surgical intervention
￿ Heart failure Grade III/IV (NYHA-classification)
￿ Medical history or pre-existing condition making
the patient ineligible for study participation or inter-
fering the patients safety
￿ Myocardial infarction, unstable angina pectoris,
balloon angioplasty (PTCA) with or without stenting
within the last 6 months
￿ Medical history of arterial thromboembolic events
including apoplectic stroke, transient ischemic attack
or cerebrovascular disorder within the last 6 months
￿ Severe bleeding event within the last 6 months
(except tumour bleeding surgically treated by
tumour resection), coagulopathy, haemorrhagic
diathesis
￿ Abdominal or tracheo-esophageal fistulas, gastroin-
testinal perforation within 6 months before study
entry
￿ Uncontrolled hypertension defined as systolic blood
pressure >150 mm Hg and/or diastolic > 100 mm Hg
under antihypertensive medication.
￿ Medical history of recurrent thromboembolic
events (> 1 episode of deep vein thrombosis, periph-
eral embolism) within the last 2 years.
￿ Severe chronic wounds, ulcerous lesions or bone
fracture.
￿ Pregnant or breast feeding women (pregnancy
needs to be excluded by testing of beta-HCG).
￿ Medical, psychiatric, familial, sociological or geogra-
phical condition which contradicts participation of
study
￿ Additional cancer treatment (chemotherapy, radio-
therapy, phytotherapy, immunotherapy, or hormonal
treatment) during study
￿ Current treatment with another investigational
drug, any other prohibited drug or participation in
another investigational study
￿ Contraindication for irinotecan treatment
￿ Known acute or delayed allergy or idiosyncrasy
against capecitabine, irinotecan and bevacizumab
and chemical related drugs
￿ Acute or subacute bowel obstruction, chronic
inflammatory bowel disease or chronic diarrhea
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Page 4 of 11￿ Known glucuronidation-deficiency (Gilbert-Meu-
lengracht-Syndrome) (special screening not required)
￿ Non-treated cerebral metastases
￿ Medical history of other malignant disease within 5
years prior to study entry, except for basalioma, and
in-situ cervical carcinoma if treated with curative
intent
￿ Known alcohol or drug abuse
￿ Limited legal capacity
Randomization
After verification of all eligibility criteria, stratification
parameters and having obtained patient’s written informed
consent, patients will be randomized by fax at the moni-
toring office (ClinAssess GmbH fax +49-2171-3633655).
Randomized treatment will be confirmed by fax within
one (1) working day. Randomization takes place with
balanced block design using PROC PLAN (SAS Institute
Inc., Cary, NC USA).
Ethics
This study is conducted according to the standards of
Good Clinical Practice (GCP), and in agreement with the
latest revision of the Declaration of Helsinki (2000,
including the notes of clarification 2002, 2004 and 2008)
and local regulations. This protocol has been submitted
and approved by the Ethical Committee (EC) of the Uni-
versity of Munich - Faculty of Medicine http://www.
ethikkommission.med.uni-muenchen.de/index.html.
The independent medical ethics committees of all par-
ticipating hospitals have approved the study protocol.
The EC may be notified of administrative changes and
Suspected Unexpected Serious Adverse Reaction
(SUSAR). Oral and written informed consent in form is
obtained from all patients prior to randomization.
Stopping rules
If excess harm is observed, or if a statistically significant
benefit (resulting from a pre-specified sequential analysis
procedure) is observed, the study is stopped and the
patient is informed of the results. Also the trial can be
stopped after consideration of justified medical, adminis-
trative or pharmaceutical reasons by principal investigator
or sponsor.
Safety
All serious adverse events (SAE) during the study period,
whether or not considered by the Investigator to be
related to study treatment, must be reported by fax to
the central data management office (ClinAssess GmbH
fax +49-2171-3633655) within 24 hours using the com-
pleted SAE report and Case Report Form (CRF). The
principal investigator is responsible for the management
of the safety reporting requirements according to the
local regulations and guidelines. Copies of all report sub-
missions by the principal investigator to regulatory
authorities (BfArM and accordingly Paul-Ehrlich-Insti-
tute, http://www.bfarm.de, http://www.pei.de) and to the
ethical committee that has approved the study will be
provided to the pharmacovigilance department of the
license holders of the study drugs. If necessary, additional
information and clarifications on cases will be forwarded
to the license holders by the principal investigator.
Data quality assurance
All patient data are collected in the central database of the
data centre at ClinAssess GmbH and the patient identifiers
are kept confidential. Computerized and visual consistency
checks will be performed on newly entered forms; queries
will be issued in case of inconsistencies.
Monitoring and source data verification
The sponsor will perform on-site monitoring with clinical
research associates. The monitoring visits frequency will
be adapted according to the site accrual. The aim of on-
site visits will be:
￿ Adherence to recruitment rate
￿ Adherence to eligibility criteria
￿ To evaluate the local facilities available to the
responsible investigator for performing clinical trials
and to comply to all requirements of the present
protocol
￿ Adherence to scheduled examination and evalua-
tion appointments
￿ Existence of written informed consent
￿ Integrity of study documentation
￿ To assess the consistency of the data reported on
t h eC R Fw i t ht h es o u r c ed a t a( s o u r c ed a t a
verification)
Statistical analysis
Statistical analyses will be performed according to the
intention-to-treat principle, i.e. all eligible patients will be
included in the analysis in the arm to which they were
randomized independently of whether they received the
assigned treatment or not. A second analysis (according-
to-protocol) will include all patients receiving at least 3
cycles of first-line chemotherapy. Toxicity analysis will be
conducted in all patients receiving at least one application
of study medication.
T h ep r i m a r yo b j e c t i v eo ft h es t u d yi st oe x a m i n et w o
hierarchically ordered hypotheses on the comparative
efficacy and toxicity. The primary efficacy endpoint is the
time to failure of strategy (TFS). The objective is to show
non-inferiority of the experimental arm. The primary
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if) non-inferiority with respect to TFS was shown. This
hierarchically ordered approach precludes an inflation of
the overall type I error in case of more than one study
hypothesis. The primary safety endpoint is a toxicity
score defined as the mean number of NCI CTC grade 2 -
4 findings per cycle during the whole TFS period. Only
symptomatic toxicities will be taken into account, and
not any events that are manifested as laboratory abnorm-
ality or change only. With respect to toxicity the objec-
tive is to show superiority of the experimental arm.
The primary endpoints will be analyzed confirmatively
with a global level of significance p ≤ 0.05 (one-sided). All
other parameters will be estimated in a descriptive analysis
with report of means, medians, ranges and confidence
intervals. All additional p-values will be estimated explora-
torily without adjustment of the level of significance, using
two-sided test procedures.
Demographic and prognostic baseline measures will be
analyzed for heterogeneity between the two treatment
arms. Clinical and laboratory toxicity graded according
NCI CTC (version 4.0) will be collected for all patients.
Quality of life will be measured using the EORTC QLC-
C30 questionnaire. Categorical data comparisons between
treatment arms will be performed applying Fisher’s exact
test, chi-square test and Mantel-Haenszel test, as appropri-
ate. Event-related data (TFS, PFS, OS) will be reported
according to the life-table method (Kaplan and Meier) and
compared using the logrank test. In case of non-confor-
mity with proportional hazard assumptions the general-
ized Wilcoxon signed-rank test may be used as modified
by Peto et al. and Prentice et al. [14-16].
Univariate estimation for prognostic factors will be
performed as described above. In case of need for multi-
variate analysis appropriate regression models e.g. logis-
tic regression model, Cox proportional hazard model
will be adopted.
In case of ethical need or slow recruitment an interim
analysis will be performed, applying a prospective group-
sequential design using the alpha error spending function
published by Lan and Demets [17,18], implementing an
O’Brien and Fleming boundary shape. Final data collection
date for primary outcome measure will be December 2013
and the estimated study completion date will be December
2016.
Sample size
Based on published data on FOLFIRI or CAPIRI plus
bevacizumab and with regard to a marginally decreased
prognosis due to exclusion of resectable patients, a med-
ian time to failure of strategy (TFS) of 10 months will be
expected. Assuming equal TFS in both arms and in order
to statistically exclude an inferior TFS corresponding to a
median of 8 months in the experimental arm, 253
observed failures per group are required, i.e. a total of
506 events, to achieve a power of 80% with a one-sided
type I level of 0.05 Under assumption of a recruitment
period of 3 years and of a minimum follow-up period of
3 years the number of patients to recruit is 258 per treat-
ment arm and a total of 516 in the study.
Baseline assessment
Baseline investigation will be performed within 14 days
before first application of study medication and include
the following items:
￿ Patient information sheet and consent form
informed consent
￿ Patient history (including tumour parameters, prior
treatments, concomitant diseases/treatment and pre-
scribed drugs)
￿ Physical examination
￿ Body weight and height
￿ Vital signs (blood pressure and heart rate)
￿ ECOG-Performance status
￿ Quality of life questionnaire (EORTC QLQ-C30)
￿ Haematology and differential blood count
￿ Serum chemistry (including sodium, potassium, cal-
cium, creatinine, urea, uric acid, estimated creatinine
clearance, lactate-dehydrogenase (LDH), c-reactive
protein (CRP), bilirubin, alkaline phosphatase (AP),
aspartate aminotransferase (AST), alanine aminotrans-
ferase (ALT), Gamma-glutamyl transpeptidase (GGT),
total protein, albumin, international normalized ratio
(INR), activated partial thromboplastine time (APTT)
￿ Tumour Markers (Carcionembryonic antigen
(CEA), carbohydrate antigen 19-9 (CA 19-9)
￿ Urine analysis (dipstick)
￿ Pregnancy test in childbearing potential women
￿ ECG
￿ Cardiac ultrasound
￿ CT scan of thorax and abdomen within 4 weeks
before randomization (definition of target lesions
according to RECIST criteria version 1.1)
￿ Bone scan and/or x-ray if clinically indicated
Assessments during study treatment phase
At day 1 every cycle
￿ Patient history (including symptoms, toxicity, con-
comitant medication)
￿ physical examination
￿ Body weight
￿ Vital signs (blood pressure and heart rate)
￿ ECOG-Performance status
￿ Haematology and differential blood count
￿ Serum chemistry (including sodium, potassium,
calcium, creatinine, urea, uric acid, estimated
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Page 6 of 11creatinine clearance, lactate-dehydrogenase (LDH),
c-reactive protein (CRP), bilirubin, alkaline phospha-
tase (AP), aspartate aminotransferase (AST), alanine
aminotransferase (ALT), Gamma-glutamyl transpep-
tidase (GGT), total protein, albumin, international
normalized ratio (INR), activated partial thrombo-
plastine time (APTT)
￿ Tumour markers such as carcinoembryonic anti-
gen (CEA) and carbohydrate antigen 19-9 (CA 19-9)
￿ Urine analysis (dipstick)
After 3 cycles
￿ CT scan of thorax and abdomen (evaluation of tar-
get lesions according to RECIST criteria version 1.1)
￿ Serum chemistry (including sodium, potassium,
calcium, creatinine, urea, uric acid, estimated creati-
nine clearance, lactate-dehydrogenase (LDH), creac-
tive protein (CRP), bilirubin, alkaline phosphatase
(AP), aspartate aminotransferase (AST), alanine ami-
notransferase (ALT), Gamma-glutamyl transpepti-
dase (GGT), total protein, albumin, international
normalized ratio (INR), activated partial thrombo-
plastine time (APTT)
￿ Tumour markers CEA and CA 19-9
￿ Quality of life questionnaire (EORTC QLQ-C30)
End of study assessment or discontinuation of treatment
￿ Patient history (including symptoms, toxicity, con-
comitant medication)
￿ Physical examination
￿ Body weight
￿ Vital signs (blood pressure and heart rate)
￿ ECOG-Performance status
￿ Quality of life questionnaire (EORTC QLQ-C30)
￿ Haematology and differential blood count
￿ Serum chemistry (including sodium, potassium,
calcium, creatinine, urea, uric acid, estimated creati-
nine clearance, lactate-dehydrogenase (LDH), creac-
tive protein (CRP), bilirubin, alkaline phosphatase
(AP), aspartate aminotransferase (AST), alanine ami-
notransferase (ALT), Gamma-glutamyl transpepti-
dase (GGT), total protein, albumin, international
normalized ratio (INR), activated partial thrombo-
plastine time (APTT)
￿ Tumour markers CEA and CA 19-9
￿ Urine analysis (dipstick)
￿ CT scan of thorax and abdomen (evaluation of tar-
get lesions according to RECIST criteria version 1.1)
￿ ECG
Assessment during follow up period
￿ Survival information
￿ Delayed toxicity (first follow-up only)
Translational research project
Tumour tissue samples from primary tumours and/or
metastatic sites are anonymized, collected and stored in
a central tumour bank at the Department of Medical
Oncology and Department of Pathology, University of
Munich. A systematic translational research project with
analysis of immunohistochemical, protein- and gene-
expression with regard to VEGFR- and EGFR-pathway
will be performed in available specimen.
Peripheral blood samples (10 ml of EDTA anticoagu-
lated peripheral blood) for gene-polymorphism analysis
with special regard to VEGFR- and EGFR-pathway are
taken additionally. Blood samples are stored centrally in
the tumour bank at the Department of Medical Oncol-
ogy, University of Munich.
Study medication
Capecitabine
Capecitabine is an oral fluoropyrimidine carbamate ration-
ally designed to generate 5-Fluorouracil preferentially in
tumour tissue through exploitation of high intratumoural
concentrations of thymidine phosphorylase (TP). TP is
found in significantly increased concentrations in a wide
range of tumour types, including colorectal, breast and
gastric cancers, compared to normal tissue [19]. Previous
human pharmacokinetic studies have shown almost com-
plete absorption through the gastro-intestinal wall after
oral administration. Direct intestinal exposure to 5-FU is
thereby avoided. Capecitabine is metabolized to 5-FU via a
three-step enzymatic cascade, with the final conversion to
5-FU mediated by TP [20].
Irinotecan
Irinotecan is a semisynthetic analogue of the natural
alkaloid camptothecin and its active metabolite SN-38
inhibits the enzyme topoisomerase-1. This leads to inhi-
bition of both DNA replication and transcription. SN-38
is inactivated by the enzyme UGT1A1 by glucuronida-
tion, so that patients with UGT1A1 polymorphism are
likely to develop severe irinotecan-related toxicities such
as diarrhea and neutropenia [21].
Bevacizumab
Bevacizumab is a humanized monoclonal antibody tar-
geting the vascular endothelial growth factor (VEGF or
VEGF-A) playing a central role in signalling pathways
controlling tumour blood vessel development and survi-
val. Interruption of this pathway prevents the formation
of new blood vessels and normalizes existing tumour
blood vessels and vessel permeability allowing cytotoxic
drug access into the tumour [22,23].
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The experimental arm (arm A) of the trial consists of
the following regimen: capecitabine (1250 mg/m2 BID
day 1-14) plus bevacizumab 7.5 mg/kg over 90 minutes
on day 1 every three weeks. Treatment continuation is
intended until disease progression or development of
toxicity. In case of progression escalation to standard
chemotherapy with CAPIRI + bevacizumab is provided.
The control arm (arm B) of the trial consists of capeci-
tabine (800 mg/m2 BID day 1-14), irinotecan 200 mg/m2
on day 1 and bevacizumab 7.5 mg/kg over 90 minutes on
day 1 every three weeks (Arm B). Treatment continua-
tion is intended until disease progression or development
of toxicity. After 6 months of treatment or case of irino-
tecan-associated toxicity, de-escalation to capecitabine
plus bevacizumab is recommended. In case of disease
progression after treatment de-escalation, re-escalation
to the combination chemotherapy is possible.
Discussion
Presently, three clinically distinct groups of metastatic
colorectal cancer patients can be differentiated: 1)
patients with resectable disease; 2a) patients who require
conversion chemotherapy or (2b) patients with highly
symptomatic or rapidly progressive disease; 3) patients
with disseminated metastasis and mostly asymptomatic
disease. While only few studies have engaged to investi-
gate these subgroups separately, most clinical trials were
performed in the whole population of mCRC patients.
It appears that group 3 represents the largest subgroup.
For this reason, several clinical studies have produced
results acceptable for this subgroup. Patients in this
group do not clearly benefit from rapid remission induc-
tion and may rather profit from prolonged disease
control.
A previous report by Grothey et al. analysed two trials
where patients either received chemotherapy alone
(N9741-trial: FOLFOX vs. IFL) or chemotherapy plus
bevacizumab (AVF2107g: IFL + bevacizumab versus Beva-
cizumab alone) [3]. In both trials, the superior regimen
improved PFS and OS regardless of tumour response.
This led to the conclusion that tumour response in mCRC
is not a necessary determinant of therapeutic benefit. This
conclusion can be extended to the point that most
probably a large fraction of patients simply benefits from
non-progressive disease. If disease control becomes an
important endpoint, then trials have to be designed where
strategies including reduced treatment intensity may reach
this goal in a defined population of group-3 patients.
The present trial investigates an escalation strategy
where patients start with a well tolerated single-agent che-
motherapy (capecitabine) combined with bevacizumab.
Patients treated on this study arm are allowed to escalate
to CAPIRI plus bevacizumab once disease progression
occurs. This escalation strategy is compared to a control
arm where patients receive first-line chemotherapy with
CAPIRI plus bevacizumab. After 6 months of treatment or
if intolerable toxicity is faced, treatment can be de-esca-
lated to capecitabine plus bevacizumab. In case of progres-
sion, it can later be re-escalated to CAPIRI plus
bevacizumab. This innovative approach therefore offers
two strategies which allow a flexible response to the indivi-
dual requirements of the patient. The study seeks to
demonstrate that patients attributed to group 3 have an
adequate treatment benefit with a well tolerated low-
intensity first-line regimen provided that further treatment
is appropriately applied if necessary. As described in the
above the CAPIRI regimen with a dose of capecitabine
800 mg/m
2, irinotecan 200 mg/m
2 previously investigated
in two AIO randomized phase II trials is expected to have
an acceptable toxicity profile [7,11].
In the pre-antibody era, an escalation strategy has
already been investigated in the CAIRO (CApecitabine,
IRinotecan, and Oxaliplatin in advanced colorectal cancer)
study. Koopmann et al. reported a trial arm where treat-
ment was escalated in sequential steps from capecitabine
(1
st-line) to irinotecan (2
nd-line) to CAPOX (3
rd-line) [9].
Comparison with the sequential application of CAPIRI
(1
st-line) and CAPOX (2
nd-line) led to the interpretation
that “combination treatment does not significantly
improve overall survival compared with the sequential use
of cytotoxic drugs” [9].
Another study of the pre-antibody era was the MRC-
FOCUS trial. This study compared arm A) 5-FU/FA fol-
lowed by irinotecan at progression to arm B) 5-FU/FA fol-
lowed by combination chemotherapy and to arm C)
combination chemotherapy from the onset. Also this large
study challenged the assumption that in a non-curative
setting maximum tolerable treatment must necessarily be
used first-line [24].
Comparable results were reported by Bouché et al. who
compared the sequence LV5FU2 followed by FOLFOX
(2
nd-line) followed by FOLFIRI (3
rd-line) to the more
conventional sequence of FOLFOX followed by FOLFIRI
(2
nd-line) [25]. Again, this trial confirmed the notion that
initially intensive regimens do not induce a superior out-
come compared to well tolerated single-agent first-line
strategies. However, it is important to state that this con-
clusion is true most likely for patients treated within
group 3.
Since the CAIRO- and the MRC-FOCUS trial, perspec-
tives on curability of disease have changed specifically with
regard to the interpretation of surgical respectability [26].
Also the introduction of antivascular and anti-EGFR treat-
ment strategies had a marked impact on treatment out-
come. The present trial picks up the theme of escalation
chemotherapy, investigates this strategy specifically in
group-3 patients and analyses the effect of chemotherapy
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bevacizumab.
In the control arm of our trial, patients may de-escalate
treatment from initial combination therapy with CAPIRI
plus bevacizumab to a maintenance therapy with capeci-
tabine plus bevacizumab. De-escalation is planned after 6
months of treatment. However it can take place earlier in
case of treatment-associated toxicity. A 6-month dura-
tion of first-line combination chemotherapy has been
described in several other trials [27]. Clearly, the optimal
time point of de-escalation and the optimal maintenance
regimen still have to be defined. The present trial will
contribute to this important topic. Re-escalation from
single-agent maintenance to combination chemotherapy
is another important aspect of this strategy. Results pre-
viously obtained from the OPTIMOX1 trial indicate that
reintroduction of chemotherapy had an independent and
significant impact on overall survival [28].
The present trial does not simply investigate two
treatment regimens, but rather compares two strategies
of treatment [29]. For this reason, time to failure of
strategy (TFS) was chosen as a primary endpoint of the
study. TFS is defined as the time between randomization
and final failure of CAPIRI-Bev treatment in both treat-
ment arms. This end point allows a wide range of
options to manage mCRC patients while remaining on
study thus providing a more complete assessment of a
strategy’s benefit [29].
In case of comparable TFS times, toxicity will be eval-
uated according to NCI CTC in a predefined score sys-
tem using symptomatic grade 2-4 toxicities per cycle.
This innovative design allows to analyze both, the thera-
peutic strategies and the associated toxicity.
When this study is performed, it is necessary to also
define those patients who are clearly not candidates
for this trial. Due to the selected control arm, all
patients considered for the trial must be able to toler-
ate first-line combination chemotherapy with CAPIRI.
The present study has not been specifically designed
for elderly or frail patients and clearly excludes those
with an ECOG performance status ≥ 2. It also excludes
patients who present with symptomatic tumour dis-
ease. These patients need a fast treatment response
which can best be achieved by intensive combination
therapy.
While the present trial requires that parameters of the
EGFR-pathway are determined, KRAS mutation of the
tumour does not affect treatment within the trial. Since
treatment efficacy of bevacizumab so far is not consid-
ered to depend on KRAS mutational status and since
patients receive bevacizumab in both treatment arms,
also patients with KRAS mutation can take part in the
study.
Conclusion
The AIO KRK 0110 trial is designed for patients with dis-
seminated, but asymptomatic mCRC who are not potential
candidates for surgical resection of metastasis. Two beva-
cizumab-based strategies are compared: one starting as
single-agent chemotherapy (Cape-Bev) allowing escalation
to CAPIRI-Bev and another starting with combination
chemotherapy (CAPIRI-Bev) and allowing de-escalation to
Cape-Bev and subsequent re-escalation if necessary.
List of abbreviations
AE: Adverse event; ALT: Alanin-Aminotransferase; AST: Aspartat-
Aminotransferase; AP: Alkaline phosphatise; APTT: Activated patial
thromboplastin time; Bev: Bevacizumab; BfArM: Bundesinstitut für
Arzneimittel und Medizinprodukte; CA 19-9: Carbohydrate Antigen 19-9;
CAPOX: Capecitabin und Oxaliplatin; CEA: Carcinoembryonic antigen; CR:
Complete Remission; CRF: Case Report Form; CRP: C-reactive protein; CT:
Computertomography; DPD: Dihydropyrimidin-Dehydrogenase; ECG:
Electrocardiogram; ECOG: Eastern Cooperative Oncology Group; EGFR:
Epidermal Growth Factor Receptor; EORTC European organisation for
research and treatment of cancer, FOLFIRI, Folinc acid, 5-Fluorouracil and
irinotecan; FOLFOX, 5-Fluorouracil, leucovorine und oxaliplatin; FU: 5-
Fluorouracil; FUFOX: Fluorouracil, folinic acid and oxaliplatin; GCP: Good
clinical practice; ICH: International Conference on Harmonization; LDH:
Lactate-dehydrogenase; LVEF: Left ventricle ejection fraction; mCRC:
Metastatic colorectal cancer; NCI-CTCAE: National Cancer Institute Common
Terminology Criteria for Adverse Events; NSAIDS: Nonsteroidal
Antiinflammatory Drugs; NYHA: New York Heart Association; ORR: Overall
response rate; OS: Overall survival; PD: Progressive disease; PFS: Progression-
free survival; PR: Partial remission; RECIST: Response Evaluation Criteria in
Solid Tumours; SD: Stable disease; SNP: Single Nucleotide Polymorphism;
SAE: Severe adverse event; SUSAR: Suspected unexpected adverse reaction;
TFS: Time to failure of strategy; TTP: Time to progression; QLQ: Quality of life
questionnaire; ULN: Upper Limit of Normal; VEGF: Vascular Endothelial
Growth Factor; VEGFR: Vascular Endothelial Growth Factor Receptor; vs.,
versus; XELIRI: Xeloda (capecitabin) and irinotecan.
Acknowledgements and Funding
We like to thank all participating investigators and referral centres for their
efforts. The authors thank Matthias Wolff and Alexander Voigt for expert
secretary assistance. The trial is funded by Roche.
Key staff at coordinating centre
V. Heinemann, MD, PhD, medical oncologist (principal investigator), S.
Stintzing, MD (trial coordinator and head of translational research project), C.
Giessen, MD (trial coordinator), M. Wolff (chief secretary), B. Deuss, MD (head
project manager ClinAssess GmbH), A. Hinke, (biostatistics)
Protocol Committee
L. Fischer von Weikersthal, MD, medical oncologist (Klinikum St. Marien
Amberg), M. Geissler, MD, PhD, gastroenterologist (Klinikum Esslingen), F.
Kullmann, MD, PhD, (Klinikum Weiden), W.-H. Schmiegel, MD, PhD, medical
oncologist (University Hospital, Klinikum Bochum), A. Kretzschmar, MD,
medical oncologist, (HELIOS Klinikum Berlin-Buch)
Participating Centres
The principal investigators of the local hospitals initiated by trial start on
December 21
st 2010 are mentioned below. Investigators are located at the
department of Surgery (S), Oncology (O) or Gastroenterology (G):
Asperger, W. (S) Halle/Saale; Bangerter, M. (G, O) Augsburg; Basovski, L. (O)
Biberach an der Riß; Behrens, R. (G) Halle/Saale; Bremer, A. (O) Münster;
Denzlinger, C. (O) Stuttgart; Dietze, L. (O) Köln; Fischer von Weikersthal, L. (O)
Amberg; Florschütz, A. (O) Dessau-Roßlau; Franz-Werner, J. (O) Speyer;
Freiberg-Richter, J. (O) Dresden; Freier, W. (O) Hildesheim; Groschek, M. (O)
Würselen; Harder, J. (O, G) Singen; Heider, A. (O) Leverkusen; Hoffmann, J. (G)
Ludwigshafen Kempf, B. (O) Landshut; Kleber, G. (G) Aalen; Kremers, S. (O)
Lebach; Kullmann, F. (O, G) Weiden; Lindig, U. (O) Jena; Lück, A. (O) Rostock;
Mauthner, L. (S) Berlin; Mayerle, J. (O) Greifswald; Michl, G. (O) München;
Möller-Fassbender, F. (O) Bünde; Reddemann, C. (O) Leverkusen; Römmele,
Giessen et al. BMC Cancer 2011, 11:367
http://www.biomedcentral.com/1471-2407/11/367
Page 9 of 11U. (O) Nürtingen; Rubanov, O. (O) Hameln; Schmitz, J. (O) Arnsberg; Schulze,
M. (O) Zittau; Severin, K. (O) Köln; Sieber, M. (O) Gummersbach; Späth-
Schwalbe, E. (G, O) Berlin; Speidel, A. (O) Henningsdorf; Spes, J. (O) Altötting;
Strohbach, F. (O) Berlin; Teschendorf, C. (O) Dortmund; Vehling-Kaiser, U. (O)
Landshut; Wagner, S. (G, O) Deggendorf; Wierecky, J. (O) Hamburg; Wilke, J.
(O) Fürth; Winter, A. (O) Düsseldorf; Zimber, J. (O) Nürnberg
Author details
1Department of Medical Oncology, Klinikum Grosshadern, University of
Munich, Germany.
2MVZ Gesundheitszentrum St. Marien, Amberg, Germany.
3WISP GmbH, Langenfeld, Germany.
4Department of Internal Medicine I,
Klinikum Weiden, Germany.
5Oncological Practice, Landshut, Germany.
6Department of Medicine, University Hospital Greifswald, Germany.
7Oncological Practice Augsburg, Germany.
8Department of Medicine III,
Marienhospital, Stuttgart, Germany.
9Department of Medicine II,
Gummersbach Hospital, Gummersbach, Germany.
10St.-Josefs-Hospital
Dormund-Hörde, Germany.
11Oncological Practice, Dresden, Germany.
Authors’ contributions
CG and VH drafted the manuscript. VH, SS and CG wrote the original
protocol for the study. AH performed the statistical analysis for the study
design and participated in drafting the manuscript. SS, FK, UVK, JM, MB, CD,
MS, CT, JFR, CS, DPM, NM and PA are providing study material or patients
and participated in drafting the manuscript. All authors read and approved
the final manuscript.
Competing interests
VH: Honoria for talks and advisory boards (Roche), research funding for
clinical trial (Roche). All other authors declare that they have no competing
interests.
Received: 28 March 2011 Accepted: 23 August 2011
Published: 23 August 2011
References
1. Adam R, Haller DG, Poston G, Raoul J-L, Spano J-P, Tabernero J, Van
Cutsem E: Toward optimized front-line therapeutic strategies in patients
with metastatic colorectal cancer–an expert review from the
International Congress on Anti-Cancer Treatment (ICACT) 2009. Annals of
Oncology 2010.
2. Petrelli NJ, Abbruzzese J, Mansfield P, Minsky B: Hepatic resection: the last
surgical frontier for colorectal cancer. J Clin Oncol 2005, 23(20):4475-7.
3. Grothey A, Hedrick EE, Mass RD, Sarkar S, Suzuki S, Ramanathan RK,
Hurwitz HI, Goldberg RM, Sargent DJ: Response-independent survival
benefit in metastatic colorectal cancer: a comparative analysis of N9741
and AVF2107. J Clin Oncol 2008, 26(2):183-9.
4. Feliu J, Salut A, Safont M, Losa F, Garcia C, Bosch C, Escudero P, Lopez R,
Bolanos M, Gonzalez-Baron M, ONCOPAZ group: First-line treatment with
bevacizumab plus capecitabine for elderly patients with metastatic
colorectal cancer: BECA trial. ASCO Meeting Abstracts 2008,
26(15_suppl):15120.
5. Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA,
Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D,
Saunders MP, Stockler MR, Chua Y, Zalcberg JR, Simes RJ, Price TJ:
Capecitabine, bevacizumab, and mitomycin in first-line treatment of
metastatic colorectal cancer: results of the Australasian Gastrointestinal
Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010,
28(19):3191-8.
6. Ducreux M, Adenis A, Mendiboure J, Francois E, Boucher E, Chauffert B,
Ychou M, Pierga J, Montoto-Grillot C, Conroy T: Efficacy and safety of
bevacizumab (BEV)-based combination regimens in patients with
metastatic colorectal cancer (mCRC): Randomized phase II study of BEV
+ FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD 13/0503 study). ASCO
Meeting Abstracts 2009, 27(15S):4086.
7. Reinacher-Schick AC, Kubicka S, Freier W, Arnold D, Dietrich G, Geissler M,
Hegewisch-Becker S, Graeven U, Schmoll H, Schmiegel W: Activity of the
combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/
Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal
cancer (ACRC): A randomized phase II study of the AIO Colorectal Study
Group (AIO trial 0604). ASCO Meeting Abstracts 2008, 26(15_suppl):4030.
8. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J,
Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J: Randomized, controlled
trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-
line treatment of metastatic colorectal cancer: results from the BICC-C
Study. J Clin Oncol 2007, 25(30):4779-86.
9. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de
Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A,
Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH, Werter MJ, Mol L,
Dalesio O, Punt CJ: Sequential versus combination chemotherapy with
capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer
(CAIRO): a phase III randomised controlled trial. Lancet 2007,
370(9582):135-42.
10. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S: Mortality
associated with irinotecan plus bolus fluorouracil/leucovorin: summary
findings of an independent panel. J Clin Oncol 2001, 19(18):3801-7.
11. Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG,
Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M,
Abenhardt W, Puchtler G, Kappauf H, Mittermuller J, Haberl C, Schalhorn A,
Jung A, Stintzing S, Heinemann V: Cetuximab Plus Capecitabine and
Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin
As First-Line Treatment for Patients With Metastatic Colorectal Cancer:
AIO KRK-0104–A Randomized Trial of the German AIO CRC Study Group.
J Clin Oncol 2011.
12. Schmiegel W, Pox C, Reinacher-Schick A, Adler G, Arnold D, Fleig W,
Folsch UR, Fruhmorgen P, Graeven U, Heinemann V, Hohenberger W,
Holstege A, Junginger T, Kopp I, Kuhlbacher T, Porschen R, Propping P,
Riemann JF, Rodel C, Sauer R, Sauerbruch T, Schmitt W, Schmoll HJ,
Seufferlein T, Zeitz M, Selbmann HK: S3 guidelines for colorectal
carcinoma: results of an evidence-based consensus conference on
February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z
Gastroenterol 2010, 48(1):65-136.
13. Schmiegel W, Reinacher-Schick A, Arnold D, Graeven U, Heinemann V,
Porschen R, Riemann J, Rodel C, Sauer R, Wieser M, Schmitt W, Schmoll HJ,
Seufferlein T, Kopp I, Pox C: [Update S3-guideline “colorectal cancer”
2008]. Z Gastroenterol 2008, 46(8):799-840.
14. Peto R, Peto J: Asymptotically Efficient Rank Invariant Test Procedures.
Journal of the Royal Statistical Society. Series A (General) 1972, 135(2):185-207.
15. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N,
McPherson K, Peto J, Smith PG: Design and analysis of randomized
clinical trials requiring prolonged observation of each patient. II. analysis
and examples. Br J Cancer 1977, 35(1):1-39.
16. Prentice RL: Linear rank tests with right censored data. Biometrika 1978,
65(1):167-179.
17. Lan G, Demets D: Discrete sequential boundaries for clinical trials.
Biometrika 1983, 70(3):659-663.
18. O’Brien PC, Fleming TR: A multiple testing procedure for clinical trials.
Biometrics 1979, 35(3):549-56.
19. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N,
Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate,
capecitabine, which generates 5-fluorouracil selectively in tumours by
enzymes concentrated in human liver and cancer tissue. Eur J Cancer
1998, 34(8):1274-81.
20. Reigner B, Blesch K, Weidekamm E: Clinical pharmacokinetics of
capecitabine. Clin Pharmacokinet 2001, 40(2):85-104.
21. Kweekel D, Guchelaar HJ, Gelderblom H: Clinical and pharmacogenetic
factors associated with irinotecan toxicity. Cancer Treat Rev 2008,
34(7):656-69.
22. Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of
bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug
Discov 2004, 3(5):391-400.
23. Shibuya M: Angiogenesis regulated by VEGF and its receptors and its
clinical application. Rinsho Ketsueki 2009, 50(5):404-12.
24. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ,
Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM, Thompson L,
Griffiths GO, Parmar MK, Stephens RJ: Different strategies of sequential
and combination chemotherapy for patients with poor prognosis
advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
Lancet 2007, 370(9582):143-52.
25. Bouche O, Castaing M, Etienne PL, Texereau P, Auby D, Bedenne L,
Rougier P, Gargot D, Gasmi M, Ducreux M: Randomized strategical trial of
Giessen et al. BMC Cancer 2011, 11:367
http://www.biomedcentral.com/1471-2407/11/367
Page 10 of 11chemotherapy in metastatic colorectal cancer (FFCD 2000-05):
Preliminary results. ASCO Meeting Abstracts 2007, 25(18_suppl):4069.
26. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW,
Grothey A, Vauthey JN, Nagorney DM, McWilliams RR: Improved survival in
metastatic colorectal cancer is associated with adoption of hepatic
resection and improved chemotherapy. J Clin Oncol 2009, 27(22):3677-83.
27. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S,
Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J: Bevacizumab
in combination with oxaliplatin-based chemotherapy as first-line therapy
in metastatic colorectal cancer: a randomized phase III study. J Clin
Oncol 2008, 26(12):2013-9.
28. de Gramont A, Buyse M, Abrahantes JC, Burzykowski T, Quinaux E,
Cervantes A, Figer A, Lledo G, Flesch M, Mineur L, Carola E, Etienne PL,
Rivera F, Chirivella I, Perez-Staub N, Louvet C, Andre T, Tabah-Fisch I,
Tournigand C: Reintroduction of oxaliplatin is associated with improved
survival in advanced colorectal cancer. J Clin Oncol 2007, 25(22):3224-9.
29. Allegra C, Blanke C, Buyse M, Goldberg R, Grothey A, Meropol NJ, Saltz L,
Venook A, Yothers G, Sargent D: End points in advanced colon cancer
clinical trials: a review and proposal. J Clin Oncol 2007, 25(24):3572-5.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/11/367/prepub
doi:10.1186/1471-2407-11-367
Cite this article as: Giessen et al.: A randomized, phase III trial of
capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus
irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of
metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial. BMC
Cancer 2011 11:367.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Giessen et al. BMC Cancer 2011, 11:367
http://www.biomedcentral.com/1471-2407/11/367
Page 11 of 11